Welcome to the Abstract Submission Site

We invite you to submit your abstract submissions for IKDS 2024. As an author submitting an abstract, you acknowledge and understand that if your abstract is accepted, you are expected to travel to IKDS 2024 to present the accepted abstract. All presenting authors must register for IKDS 2024 and are responsible for their own round-trip transportation and accommodations. Registration, travel, and accommodation for presenting authors is not complimentary.

Please familiarize yourself with IKDS 2024 abstract submission guidelines before beginning the submission of your abstract:

1. Submission Fee

• There is no fee to submit an abstract to IKDS 2024.

2. Submission Deadline

• Abstract submission site closes Wednesday, January 31, 2024 11:59 pm (EDT) 
• Abstracts must be received electronically through the online submission system.
• Faxed, mailed or emailed abstract submissions will not be accepted.
• The online submission system will identify your submitted abstract as either complete or incomplete. If incomplete, the system will flag the tasks that require attention and completion. Incomplete submissions at the time of the deadline will not be accepted, without exception. 

3. Submission Method

• Upon successful submission through the online abstract submission website, the corresponding author will receive an acknowledgement of receipt by email.
• Please email ikds2024@sta.ca if you do not receive your email confirmation within 48 hours after submitting your abstract.
• Changes to abstracts can be made before the January 31, 2024 11:59 pm (EDT) deadline within the submission site, but not after that date.
• A link to your profile will be posted in your confirmation email.

4. General Submission Guidelines

• There is no limit to the number of abstracts an individual may submit.
• Submitters may return to the online system to edit abstracts, revise information, or delete abstracts at any time before the submission deadline of January 31, 2024 11:59 pm (EDT). After the submission deadline, the online submission system will be closed and completed abstracts will be included in the peer review process.
• No change in abstract title, content, and names or order of authors will be accepted after the submission deadline of January 31, 2024 11:59 pm (EDT).
• Accepted abstracts that receive awards, are presented orally and/or are considered top of their category will be published in a Canadian Journal of Cardiology (CJC) supplement.
• All accepted abstracts will be compiled and available for viewing in the IKDS 2024 mobile app and/or the IKDS event platform.
• A submitter should not “split” data to create several abstracts from one. If splitting is judged to have occurred, scoring of related abstracts will be reduced.
• Abstracts containing identical or nearly identical data submitted from the same institution and/or individuals may be disqualified.
• Submission of an abstract constitutes a commitment by the author(s) to the integrity of the data and that all agree with the submission.
• If the presented research was funded or supported, in whole or in part, by a grant, please indicate so during the submission process.
  • Accepted abstracts with funding will be declared in the publication(s).
  • Responses provided to this question will not affect the acceptance of the abstract.
• Abstracts should be written and submitted by physicians, researchers, trainees, healthcare professionals or patient partners.
  • Industry-funded research that was approved by a Research Ethics Board, and for which the principal investigator/principal author is not an employee of the funding company, will be accepted for review.
• If submitting a related abstract to other national and/or international meetings, the submitting author is responsible for ensuring that it does not infringe with other meetings’ rules and embargo policies.
• Abstracts based on manuscripts accepted for publication in 2024 are acceptable.
• Abstracts based on publications prior to 2024 are not acceptable.

5. Word Count and Writing Standards

• The word limit for a submission is a maximum of 400 words.
• Tables, graphs, and images must be added under the "Supporting images, graphs or tables" task during the submission process, and are not included in the word limit.
  • Graphs and tables must be simple, easily interpreted, and of high resolution.
• Abstracts are published as submitted. Please proofread your work carefully to avoid errors.
  • Abstracts WILL NOT be edited by conference staff.
  • Abstracts must be written in English with accurate grammar and spelling.
  • Revisions or corrections to abstracts will not be permitted once abstracts are accepted.
• For the sake of word count, it is recommended you NOT mention what Kawasaki Disease is about.
• Using the following section titles in your submission will help direct the focus of the abstract:
  • BACKGROUND/AIM: A brief statement of the purpose
  • METHODS: A statement of the method(s) of investigation
  • RESULTS: A summary of the results presented in sufficient detail to support conclusions
  • CONCLUSION: A brief statement of results achieved. Statements such as “results to be discussed” or “data will be presented” are not sufficient and will result in rejection of the abstract. 
• Abstracts must adhere to the following format:
  • All abstract titles must be capitalized (e.g. CAPITALIZED).
  • Author(s) first name and last name should be listed using capital letters (e.g. CAPITALIZED).
  • If an author’s name appears on more than one abstract, their names must appear the same way on all abstracts. This consistency will streamline the process of facilitating proper indexing in both the IKDS mobile app and all publications. Do not list authors with initials only.
  • The use of standard abbreviations is required. Examples include kg, g, mg, mL, L, meq, m, mmol/L, and % 
• Standard abbreviations DO NOT NEED to be defined in parenthesis in the abstract. However, other repeated words and terms for abbreviation, even if commonly used (e.g., Pulmonary Artery Hypertension (PAH) should be defined. 
• The following terms can be represented in their abbreviated forms throughout the abstract:
  • CA for coronary artery
  • CRP for C-reactive protein
  • ECHO for echocardiography
  • ESR for erythrocyte sedimentation rate
  • IVIG for Intravenous Immunoglobulin
  • KD for Kawasaki Disease
  • WBC for white blood cells
• Following the Canadian National Standard of Support for Accredited CPD Activities, it is required that any description of therapeutic options utilize generic names and not reflect exclusivity and branding.
• Special symbols may be included in the abstract body; however, conference staff will not be responsible for any symbols, graphics, fonts or special characters which do not appear or are lost in translation due to software or hardware incompatibilities with the file submitted. 
• Language can have a profound impact on the lives of people. Inappropriate language has a negative impact on self-efficacy, well-being, and confidence which can seriously undermine experiences with healthcare providers and, more broadly, can contribute to stigma. We encourage you to use language that promotes and guides the use of inclusive, equitable, and value-based language in clinical practice, healthcare, and research settings. We hope that greater attention to the language used will contribute to enhancing public understanding, decreasing the stigma, stereotypes, and associated prejudices.

6. Authorship Requirements and Conflict of Interest Disclosure Statement

• There is no limit to the number of abstracts an author may submit; however, it is recommended that separate presenters are designated to avoid scheduling conflicts that arise due to multiple submissions.
• IKDS 2024 encourages trainees and young investigators to present.
• If accepted, the presenter must be a co-author listed on the abstract at the time of submission. The author listed first in the author block is referred to as the first author and does not have to serve as the presenting author. The corresponding author will receive notification of abstract status. Should the corresponding author prefer, a different email address may be submitted for abstract correspondence and notification of abstract status. An author can be the first, corresponding, and presenting author. Please check off all that apply during abstract submission.
• When deciding on authorship and other contributors, consideration on equity, diversity and inclusion is encouraged. 
• The submitting or lead author assumes the responsibility for disclosing any conflicts-of-interest on behalf of their co-authors.
• In the presence of a conflict of interest, the submitter must disclose the commercial relationship. By disclosing any direct or indirect conflicts of interest, the submitter authorizes the host organization to disclose conflict.
• Disclosure information for accepted abstracts will be made available upon request.

7. Presentation Types

•  Accepted abstracts will be designated for either poster or oral presentation.

8. Abstract Selection Criteria

• Abstract grading is performed by blinded review by a group of experts within a particular field. The review committee is responsible for grouping the abstracts appropriately for a particular specialty or association. 
• Abstracts, and presentation type (oral versus poster), are selected based on scientific criteria of merit, originality of work, adequacy of data, and clarity of exposition.

9. Abstract Rejection Criteria 

• Abstract will be rejected if: 
  • Abstract did not conform to instructions. 
  • Abstract lacks data or includes inconsistent/ambiguous data.
  • Abstract is not well-organized, information is dated, the importance of the topic is not clear, discussion of study results is vague, or conclusion is not supportable based on the data presented.
  • Clinical research did not abide by the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans.
  • The final decision with respect to selection, programming, and/or publication of any abstract will be made by the Abstract Selection Committee. 

10. Abstract Status

• All abstracts submitted must comply with these guidelines to be considered for acceptance. 
• Notification of acceptance or rejection of abstracts will be emailed February 6-9, 2024.
• Submitters can also check the status of their submission online through the online submission system as of February 6, 2024.
• All appropriate accompanying materials, including guidelines for oral or poster presentations, will be sent by email to the presenting author in April 2024. 

11. Abstract Withdrawal

• Withdrawal of accepted abstracts must be received at ikds2024@sta.ca, no later than June 3, 2024 to avoid publication. 

12. Embargo Policy for Submitted Abstracts

• Abstract authors can present the findings of their submitted papers to experts for comment and at professional meetings to colleagues. It is the responsibility of the authors to ensure embargo policies are honored by third parties.

Should you have questions about the information presented here, or completing the abstract form, please contact ikds2024@sta.ca. 

Click Join Now below to begin.